Rolf Teschke | Medicine and Dentistry | Best Paper Award

Prof. Rolf Teschke | Medicine and Dentistry | Best Paper Award

Professor at Klinikum Hanau | Germany

Prof. Rolf Teschke is an internationally recognized expert in hepatology whose distinguished career has significantly influenced contemporary understanding of liver diseases, hepatotoxicity, and drug-induced liver injury. Educated at leading medical institutions and trained in internal medicine with specialization in gastroenterology and hepatology, he advanced early in his career through rigorous scientific and clinical environments that shaped his enduring interest in hepatic metabolism and toxicology. His research journey includes extensive work in experimental hepatology, where he contributed pivotal insights into microsomal ethanol-oxidizing systems, cytochrome P450 related pathways, and the biochemical mechanisms underlying alcohol-associated and toxin-induced liver damage. Over several decades, Prof. Rolf Teschke has held prominent academic and clinical positions, leading major medical departments and contributing to both patient care and research innovation. His expertise is particularly well known for advancing causality assessment methodologies in drug-induced liver injury, especially through his influential work with the RUCAM system, which has become a globally referenced tool in hepatotoxicity evaluation. Throughout his career, he has produced a substantial body of peer-reviewed literature, reflecting profound scientific productivity and impact. His publication record includes 171 documents, supported by 6,888 citations across 4,040 citing documents, and an impressive h-index of 48, underscoring the depth, relevance, and international recognition of his work. Prof. Rolf Teschke’s research interests span alcoholic liver disease, herbal and drug hepatotoxicity, biochemical enzymology, and clinical hepatology, integrating laboratory discoveries with real-world clinical applications to improve diagnostic standards and therapeutic strategies. He has authored and co-authored more than 250 publications, including articles, book chapters, and comprehensive reviews, contributing to foundational knowledge used by clinicians, toxicologists, and regulatory bodies worldwide. In addition to research, he has served in editorial roles for several journals, helping guide scientific discourse in hepatology and liver toxicology. Overall, Prof. Rolf Teschke’s career reflects a sustained commitment to advancing scientific excellence, improving patient outcomes, and shaping global best practices in the study of liver injury, marking him as one of the leading contributors to modern hepatology.

Profile; Scopus | Orcid

Featured Publications:

Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.

Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.

Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.

Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).

Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.

Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.

Teschke, R. Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types. Review.
Annotation: Introduces a new five-type classification system for liver injury associated with severe immune-mediated skin reactions.

Teschke, R. Acute Liver Failure Due to Assumed Drug Induced Liver Injury but Lack of Any Validated Causality Algorithm: Evidence by 36 Cohort Reports with 21,709 Cases. Review.
Annotation: Critically analyzes large cohorts revealing gaps in validated causality assessment for assumed DILI-related acute liver failure.

Teschke, R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on RUCAM and HLA B57:01 Genotype.* Review.
Annotation: Examines metabolic and immune mechanisms underlying flucloxacillin-induced hepatocellular injury.

Teschke, R., et al. Successful Corticosteroid Therapy for Severe Liver Injury Secondary to Herbal Traditional Chinese Medicine Mega Defends X: A Case Report. Article, 2024.
Annotation: Documents a clinically significant case showing steroid responsiveness in herb-induced liver injury assessed by updated RUCAM.

Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award

Dr. Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award 

Assistant professor at Beth Israel Deaconess Medical Center | United States

Dr. Zsuzsanna Zsengeller is a distinguished medical scientist whose career spans clinical medicine, molecular biology, and translational research. She has established herself as a global leader in the investigation of preeclampsia, mitochondrial dysfunction, and kidney-related disorders. With appointments at world-renowned institutions, she has advanced knowledge in gene therapy, molecular signaling, and maternal-fetal health. Her professional journey demonstrates a seamless integration of clinical insight and laboratory research, producing innovative therapeutic approaches. Through consistent scholarly output, grant leadership, and mentorship of future scientists, Dr. Zsuzsanna Zsengeller embodies excellence in academic medicine and translational science, with her work directly impacting patient health worldwide.

Profile:

Orcid

Education:

Dr. Zsuzsanna Zsengeller earned her Doctor of Medicine degree in General Medicine, followed by a Ph.D. in Medical Science with a strong foundation in microbiology. Her academic path was marked by a commitment to understanding complex disease mechanisms through both experimental and clinical approaches. Her postgraduate training included prestigious postdoctoral fellowships in pulmonary biology and respiratory diseases, where she refined her expertise in molecular and cellular biology. These academic experiences provided the groundwork for her lifelong research into oxidative stress, immune signaling, and vascular biology, ultimately shaping her into a well-recognized expert in mitochondrial and maternal health research.

Experience:

Dr. Zsuzsanna Zsengeller has extensive experience as both a clinician and scientist, having held positions across leading hospitals, research institutions, and industry collaborations. Her work includes significant contributions to pulmonary biology, renal pathology, and preeclampsia research. She has served in roles as staff scientist, senior scientist, consultant, and academic faculty member, currently serving as Assistant Professor of Medicine at Harvard Medical School. Her collaborations with multidisciplinary teams have resulted in advancements in therapeutic strategies for cardiovascular, renal, and maternal health. With experience in academia, industry, and clinical translation, she has built a unique career that bridges discovery and application.

Research Interest:

Dr. Zsuzsanna Zsengeller’s research interests center on the pathogenesis and treatment of preeclampsia, kidney disease, and mitochondrial dysfunction. She investigates redox biology, nitric oxide modulation, and oxidative stress pathways to understand how cellular signaling impacts maternal and fetal outcomes. Her translational studies have examined novel dual-function redox modulators, antioxidants, and mitochondrial-targeted therapies. Beyond maternal health, her work extends into nephrology and cardiovascular disease, with particular focus on mechanisms of APOL nephropathy and endothelial dysfunction. Through advanced molecular techniques and therapeutic modeling, her research seeks to translate laboratory discoveries into clinical strategies, offering hope for improved patient outcomes worldwide.

Awards and Honors:

Dr. Zsuzsanna Zsengeller has been recognized with numerous honors that reflect her leadership in biomedical science and translational medicine. She has received institutional research funding awards, including competitive support for her pioneering work on mitochondrial-targeted antioxidants for preeclampsia therapy. Her contributions have also been acknowledged through awards from scientific societies, highlighting her excellence in poster presentations, mentorship, and innovative project design. Her research projects have consistently received funding from federal agencies and medical foundations, underscoring the clinical relevance and impact of her work. These awards honor her as a trailblazer in developing therapies addressing urgent global health challenges.

Publications:

Title: Development of Diaryl Hydrazones for Alleviation of Mitochondrial Oxidative Stress in Preeclampsia
Year of Publication: 2025
Citation: 1

Title: Gasdermin D deletion prevents liver injury and exacerbates extrahepatic damage in a murine model of alcohol-induced ACLF
Year of Publication: 2025
Citation: 1

Title: A Novel Multi-organ Male Model of Alcohol-induced Acute-on-chronic Liver Failure Reveals NET-mediated Hepatocellular Death, Which is Prevented by RIPK3 Inhibition
Year of Publication: 2025
Citation: 5

Title: Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2
Year of Publication: 2024
Citation: 5

Title: Solvent- and Catalyst-Free Environmentally Benign High Hydrostatic Pressure-Assisted Synthesis of Bioactive Hydrazones and the Evaluation of Their Stability Under Various Storage Conditions
Year of Publication: 2024
Citation: 3

Title: A Novel Dual-Function Nitric Oxide Donor Therapy for Preeclampsia—A Proof-of-Principle Study in a Murine Model
Year of Publication: 2023
Citation: 3

Title: Hepatocyte nuclear factor 4α mediated quinolinate phosphoribosylltransferase (QPRT) expression in the kidney facilitates resilience against acute kidney injury
Year of Publication: 2023
Citation: 8

Conclusion:

Dr. Zsuzsanna  Zsengeller stands as a pioneering physician-scientist whose research has transformed the understanding of oxidative stress, mitochondrial dysfunction, and maternal-fetal disorders. Her leadership in translational medicine continues to advance new therapies that address major public health burdens, particularly preeclampsia and kidney disease. Through groundbreaking research, impactful publications, and mentorship of future leaders, she exemplifies the highest standards of academic and clinical excellence. Her career demonstrates how dedication to discovery can be translated into real-world medical advancements, making her a highly deserving candidate for prestigious recognition in biomedical and clinical research innovation.

Abdul Sattar Khan | Medicine and Dentistry | Impactful Researcher Award

Abdul Sattar Khan | Medicine and Dentistry | Impactful Researcher Award

 Head, Family & Community Medicine Department at  King Faisal University, Saudi Arabia.

Dr. Abdul Sattar Khan is an esteemed medical professional specializing in Family Medicine and Medical Education, currently serving as Associate Professor and Head of the Family & Community Medicine Department at King Faisal University, Saudi Arabia. With over 30 years of experience, he has played pivotal roles in medical education and research, influencing healthcare systems across Pakistan, Saudi Arabia, and beyond. His extensive leadership in curriculum development, quality assurance, and strategic planning highlights his commitment to enhancing medical training. Additionally, Dr. Khan’s work spans clinical research, public health initiatives, and advisory roles, contributing to the betterment of healthcare education and policy.

Profile👤

Scopus

Orcid

Education 🎓

Dr. Abdul Sattar Khan holds multiple prestigious qualifications, including a Fellowship in Family Medicine (FRCGP) from the Royal College of General Practitioners, London, in 2017. He completed his MSc in Medical Education from the University of Dundee, UK, in 2019, and earned his MPH from the University of Karachi in 1995. His educational background also includes diplomas in Medical Education, Quality Assurance, and Leadership, as well as certificates in research management and advanced teaching techniques from global institutions like the University of Colorado and McMaster University. His multidisciplinary education allows him to excel in both clinical practice and medical education.

Experience💼

Dr. Khan’s career spans over three decades in academic and clinical leadership. He has served as Associate Professor and Head of Family & Community Medicine at King Faisal University since 2012. His previous roles include Assistant Professor at Ataturk Public University, Turkey, and a faculty member at Baqai University, Pakistan. He has also worked as a family physician and trainer in Saudi Arabia’s healthcare system. Internationally, he collaborates with the Royal College of General Practitioners, UK, and serves as a mentor and tutor for various postgraduate programs. His diverse roles showcase his ability to lead in both academic and healthcare environments.

Research Interests 🔬

Dr. Khan’s research interests are focused on chronic disease prevention, genetic disorders, precision medicine, and the role of artificial intelligence in healthcare. He is passionate about enhancing medical education, particularly in curriculum development and assessment methods. His research has a strong clinical and societal impact, ranging from genetic factors in diabetes complications to improving the quality of life for people with disabilities. Dr. Khan’s interdisciplinary research approach, combining clinical practice with cutting-edge technology and education methodologies, positions him as a leader in addressing critical healthcare challenges.

Awards and Honors 🏆

Throughout his career, Dr. Khan has received numerous awards and honors, including first prize for his oral presentation at the COAMS 2nd Research & Innovation Day in 2023. He has been awarded scholarships for his Fellowship in Faculty Development from the USA and for his MPH from Baqai University. His contributions to healthcare education and research have earned him recognition from several prestigious institutions, such as the Royal College of General Practitioners, UK. Dr. Khan’s accolades reflect his dedication to advancing medical knowledge and his leadership in family medicine and medical education.

Conclusion 🔚 

Dr. Abdul Sattar Khan is an excellent candidate for the Impactful Researcher Award due to his impressive academic qualifications, leadership roles, and research contributions in family medicine, chronic disease management, and medical education. His commitment to public service and global collaborations further strengthens his candidacy. Focusing on high-impact publications and expanding his leadership in international research could further enhance his profile.

Publications Top Notes 📚

Weight reduction among females undergoing laparoscopic ventral hernia repair: The role of Calcium and Vitamin D3
Almulhim, S.A., Alnaim, M.M., Khan, A.S., Al Abdulqader, A.A., Almulhim, A.S.
Pakistan Journal of Medical Sciences, 2024, 40(5), pp. 922–926
Citation: 0

The impact of coronavirus crisis on human interpersonal relationships among AlAhsa population
Khan, A.S., Alnefaie, B.T., Al-Ali, D.S., Almusallam, S.A., Alghannam, F.N.
Annals of African Medicine, 2024, 23(1), pp. 76–81
Citation: 0

Medical Interns’ Perceptions and Attitudes During the COVID-19 Pandemic: A Qualitative Study
Almaqhawi, A., Khan, A., Albarqi, M., Almulhim, A., Ali, S.I.
Turkiye Klinikleri Journal of Medical Sciences, 2023, 43(1), pp. 112–118
Citation: 0

Earning Engagement via E-health (EEE Project)
Khan, A.S.
Medical Science Educator, 2022, 32(4), pp. 763–764
Citation: 0

Psychological impact of the COVID-19 pandemic on healthcare professionals in the Al Ahsa Region, Saudi Arabia
Almaqhawi, A., Khan, A.S., Albarqi, M., Ali, S.I., Elbarbary, H.S.
Family Medicine and Primary Care Review, 2022, 24(1), pp. 27–31
Citation: 3

Hydroxyurea usage awareness among patients with sickle-cell disease in Saudi Arabia
Alsalman, M., Alkhalifa, H., Alkhalifa, A., Alnaim, A., Khan, A.S.
Health Science Reports, 2021, 4(4), e437
Citation: 4

The potential preventive effect of pregnancy and breastfeeding on multiple sclerosis
Alhomoud, M.A., Khan, A.S., Alhomoud, I.
European Neurology, 2021, 84(2), pp. 71–84
Citation: 5

Screening for depression, anxiety, and obsessive-compulsive disorders among secondary school students in Al-Hasa Region, Saudi Arabia
Khan, A., Alalawi, A., Alalawi, M., Albahrani, M., Alhasawi, F.
Journal of Family and Community Medicine, 2021, 28(1), pp. 28–34
Citation: 4

The impact of e-learning modalities on medical students in KSA during the COVID-19 pandemic
Almulhim, A.Y., Almulhim, S.A., Almulhim, A.A., Khan, A.S.
Journal of Taibah University Medical Sciences, 2020, 15(5), pp. 437–438
Citation: 7

Psychological insulin resistance among type 2 diabetic patients attending primary healthcare centers, Al-Ahsa, Saudi Arabia
Alomran, A., Almubarak, D., Alrashed, B., Khan, A.
Journal of Family and Community Medicine, 2020, 27(3), pp. 192–199
Citation: 5